We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Unmet Need Outweighs ‘Fragile’ Data As Advisers Urge Humira OK for UC
Unmet Need Outweighs ‘Fragile’ Data As Advisers Urge Humira OK for UC
September 12, 2012
Despite “fragile” trial data, the FDA should approve Abbott Laboratories’ proposed new indication for its blockbuster Humira to treat ulcerative colitis (UC), because new therapies for the chronic condition are needed and clinicians are comfortable with the drug’s safety profile, agency advisers say.